Journal of clinical oncology : official journal of the American Society of Clinical OncologyHumansFemaleBevacizumabAntineoplastic Combined Chemotherapy ProtocolsOvarian Neoplasms
Atezolizumab With Bevacizumab and Nonplatinum Chemotherapy for Recurrent Ovarian Cancer: Final Results From the Placebo-Controlled AGO-OVAR 2.29/ENGOT-ov34 Phase III Trial.
Philipp Harter, Frederik Marmé, Andrés Redondo, Alexander Reuss, Kristina Lindemann, Christian Kurzeder, Els Van Nieuwenhuysen, Christian Marth, Klaus Pietzner, Isabelle Ray-Coquard, Carmen Garcia-Duran, Goda Jonuskiene, Florian Heitz, Charlotte Béllier, J Alejandro Pérez-Fidalgo
Published: 202610.1200/JCO-25-01210
Abstract
PURPOSE: To evaluate atezolizumab combined with bevacizumab and non-platinum-based chemotherapy for recurrent ovarian cancer. METHODS: The double-blind randomized phase III AGO-OVAR 2.29/ENGOT-ov34 trial (ClinicalTrials.gov identifier: NCT03353831) e…
Preview only. Read the full abstract at the source